Rain Oncology Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$77.1M | −$51.5M | −$19.0M |
| Net income | −$75.7M | −$51.4M | −$21.1M |
| Total assets | $135.2M | $147.1M | $61.1M |
| Total liabilities | $22.1M | $16.6M | $3.8M |
| Equity | $113.0M | $130.5M | −$37.4M |
| EPS (diluted) | $-2.71 | $-2.65 | — |
| Shares out. | 26.5M | 26.5M | 3.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −67.0%
- Return on assets
- −56.0%
- Return on capital (ROCE)
- −68.1%
- Liabilities / assets
- 16.4%
- Debt / equity
- 0.20×
- Book value / share
- $4.26
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 2.95safe
- Accruals / assets
- −9.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 26, 2024
- Other material eventJan 19, 2024
- Entered a material agreement · Regulation FD disclosureDec 14, 2023
- Results of operationsNov 9, 2023
- Results of operationsAug 10, 2023
- Costs from exit or disposal · Director / officer change · Shareholder vote · Regulation FD disclosureJun 5, 2023
- Regulation FD disclosureMay 22, 2023
- Results of operationsMay 11, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2024
- SC 13G/AFeb 14, 2024
- SC 13G/ARAIN ONCOLOGY, INC.Feb 7, 2024
- 15-12GNOTICE OF TERMINATION OF REGISTRATION OF A CLASS OF SECURITIESFeb 5, 2024
- SC 13D/AAMENDMENT NO. 2Feb 2, 2024
- 4Feb 2, 2024
- EFFECTJan 30, 2024
- 4Jan 29, 2024
- SC 13D/AAMENDMENT NO. 8 TO SCHEDULE 13DJan 29, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENT TO A S-8Jan 26, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENT TO A S-8Jan 26, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENT TO A S-8Jan 26, 2024
- 4Jan 26, 2024
- 4Jan 26, 2024
- 4Jan 26, 2024